Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.89
+0.13 (+0.88%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Exposures
Product Safety
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
August 07, 2024
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this...
Via
Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
July 31, 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...
Via
Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
July 09, 2024
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to...
Via
Benzinga
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
July 06, 2024
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...
Via
Talk Markets
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
July 02, 2024
Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020.
Via
Benzinga
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via
Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.
Via
Benzinga
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
June 17, 2024
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes
Via
Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.
Via
InvestorPlace
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
June 03, 2024
Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms.
Via
Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
May 19, 2024
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones.
Via
Talk Markets
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
May 15, 2024
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.
Via
Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
Via
Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.
Via
InvestorPlace
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
May 09, 2024
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
Via
Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
May 09, 2024
Takeda Pharmaceutical just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Via
Investor's Business Daily
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
February 12, 2024
Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.
Via
Benzinga
Exposures
Product Safety
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
February 09, 2024
Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.
Via
Benzinga
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
February 01, 2024
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.